NANO — Nanobiotix SA Share News
0.000.00%
Last trade - 00:00- €971.36m
- €967.08m
- €7.84m
U.S. STOCKS ON THE MOVE-Intel, Nike, Aptevo
Nanobiotix jumps after positive early-stage data for skin cancer therapy
Brief: Nanobiotix Announces New Results From A Phase 1 Study Evaluating JNJ-1900 (Nbtxr3)
Brief: Nanobiotix Says Authorities Okay Reclassification of JNJ-1900 To Medicinal Product
Brief: Nanobiotix SA Says €39.8 Million In Cash And Cash Equivalents As Of March 31, 2025
Brief: Nanobiotix Provides Business Update And Reports Full Year 2024 Financial Results
Brief: Nanobiotix SA Announces First Data From Completed Dose Escalation Part Of A Phase 1 Study Of NBTXR3 As A 2L+ Therapy For Locally Advanced NSCLC
Brief: Nanobiotix amends global licensing agreement for JNJ-1900 (NBTXR3)
Brief: Nanobiotix SA Files For Mixed Shelf Of Up To $200Mln
Brief: Nanobiotix To Introduce Vision For Transforming Drug Design And Development With Next Nanotherapeutic Platform On 19 December 2024
Advisory: Alert on Nanobiotix completing phase 1 study of NBTXR3 repeats earlier story
Guggenheim initiates Nanobiotix coverage with 'buy', shares rise
Guggenheim initiates Nanobiotix coverage with 'buy', shares rise
Brief: Nanobiotix Announces New Data Showing Disease Control And Tumor Response In Patients Treated With Rt-Activated Nbtxr3 Followed By Anti-Pd-1 For 2L+ R/M Hnscc Naïve Or Resistant To Prior Anti-Pd-1 Therapy
Brief: Nanobiotix To Be Able To Fund Operations Into Q3 2025
Brief: Nanobiotix Announces Progress In Global NBTXR3 Development Collaboration
Brief: Nanobiotix Announces Progress In Global Nbtxr3 Development Collaboration Highlighting Robust Pipeline And Pathway To Long-Term Growth
Brief: Nanobiotix: FDA Protocol Acceptance For New Randomized Phase 2 Study Evaluating NBTXR3
Brief: Nanobiotix Provides Business Update And Reports Full Year 2023 Financial Results